We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

RNA Interference is Coming of age as a Therapeutic Modality

RNA Interference is Coming of age as a Therapeutic Modality

RNA Interference is Coming of age as a Therapeutic Modality

RNA Interference is Coming of age as a Therapeutic Modality

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "RNA Interference is Coming of age as a Therapeutic Modality"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Business Intelligence firm La Merie S.L. has reported that the RNAi therapeutic pipeline is rapidly filling and advancing towards clinical development.

Four RNAi therapeutic projects are in early clinical development. At least 32 RNAi projects are in preclinical development in a variety of therapeutic areas.

Viral diseases and cancer are the preferred indications. A total of 14 RNAi projects are approaching IND status within one year.

At least 20 projects are in advanced research stages. These results and more were found in a search conducted by La Merie Business Intelligence.

The competitor analysis can be acquired online, La Merie ’s News Center and Online Store.

RNAi technology has been rapidly developed and adopted as a laboratory tool for potent and specific downregulation (silencing) of the expression of a gene at the post-transcriptional or even transcriptional level.

Now, RNAi has entered the clinical arena with therapeutic applications. Clinical use of RNAi was pioneered by Acuity Pharmaceuticals with Cand5.

The small interference RNA for VEGF completed phase II studies in wet AMD and diabetic macular edema.

In contrast to Acuity which is developing as an ophthalmic disease company, major RNAi players Alnylam Pharmaceuticals and Sirna Therapeutics as well as other companies are using delivery and protection technologies to broaden therapeutic applications of RNAi molecules by systemic delivery.

The drug delivery technologies use peptides, nanoparticles, liposomes and other carriers from companies such as Calando Pharmaceuticals, NovosomNastech Pharmaceuticals and SR Pharma.

The availability of siRNA or locked nucleic acid RNA (LNA RNA) reduced the risk of immunogenicity of RNAi molecules.

The delivery technologies appear to solve the problem of large molecular weight and negative charge of siRNA duplexes which represents a major challenge for effective cellular uptake and intracellular delivery.

Chemical optimization of the RNAi molecules as well as coating technologies contributed to in vivo stabilization of the RNA molecules.

Apart from the rapidly filling pipeline, the increasing maturity of the RNAi field is also evidenced by alliances of Big Pharma companies GlaxoSmithKline and Novartis with RNAi players having a solid intellectual property position.